Healthcare Contract Manufacturing Market Size Worth USD 627.55 Billion by 2034 | CAGR: 11.53%

The healthcare contract manufacturing market size is expected to reach USD 625.55 Billion by 2034, according to a new study by Polaris Market Research. The report “Healthcare Contract Manufacturing Market Share, Size, Trends, Industry Analysis Report: By Type, By Process Type, By End User, and By Region; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Healthcare contract manufacturing involves outsourcing drug and medical device production to specialized organizations, ensuring high-quality, cost-effective, and timely delivery. It is widely used in pharmaceuticals, biologics, and medical device production.

Request a free sample copy or read the full market insights :  healthcare contract manufacturing report

The market growth is driven by rising demand for chronic disease treatments, increasing outsourcing of drug production, expansion of pharmaceutical and biotechnology industries, and growing adoption of advanced manufacturing technologies.

Top of FormHealthcare Contract Manufacturing Market Report Highlights

• Based on type, the pharmaceutical segment held the largest share in 2024 due to high demand for chronic disease drugs and biologics.
• In terms of process type, formulation development led in 2024 due to the need for consistent and high-quality drug products.
• Based on end user, pharmaceutical companies accounted for the largest market share in 2024 driven by high outsourcing demand and regulatory compliance requirements.
• North America held the largest share in 2024, fueled by established pharmaceutical and biotechnology industries and advanced manufacturing infrastructure.
• Asia Pacific witnessed the fastest growth due to expanding pharma industries, government incentives, and cost-effective manufacturing capabilities.
• A few global key market players include Lonza Group, Catalent, Inc., Samsung Biologics Co., Ltd., WuXi Biologics, Thermo Fisher Scientific Inc., Recipharm AB, Boehringer Ingelheim International GmbH, Pfizer Inc., AGC Biologics, Jabil Inc., Novartis AG., Integer Holdings Corporation, Freudenberg Medical, Sterling Industries, Tegra Medical, and Scapa Healthcare.

Polaris Market Research has segmented the market report on the basis of type, process type, end user, and region:

By Type (Revenue, USD Billion, 2020–2034)

• Medical Devices
  • Therapeutic Area
    • Oncology
    • Infectious Diseases
    • Neurological Disorders
    • Cardiovascular Disease
    • Metabolic Disorders
    • Autoimmune Diseases
    • Respiratory Diseases
    • Ophthalmology
    • Gastrointestinal Disorders
    • Hormonal Disorders
    • Hematological Disorders
    • Others
  • Service
    • Accessories manufacturing
    • Assembly manufacturing
    • Component manufacturing
    • Device manufacturing
• Pharmaceutical
  • API/Bulk Drugs
  • Advanced drug delivery formulations
  • Packaging
  • Finished dose formulations
    • Solid
    • Liquid
    • Semi-solid formulations

By Process Type (Revenue, USD Billion, 2020–2034)

• Formulation Development
• Packaging Solutions
• Manufacturing Services

By End User (Revenue, USD Billion, 2020–2034)

• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Companies
• Research Institutions

By Region (Revenue, USD Billion, 2020–2034)

• North America
  • The U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherland
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America
  • Latin America
• Saudi Arabia
  • UAE
  • South Africa
  • Israel
  • Rest of South Africa